HLA-A and neoplasm: In preclinical models, intra-tumoral injection (and to a significantly lesser extent, IV injection) of AFP-CAR-T in NSG mice bearing HLA-A*02:01 HCC SK-HEP-1-MG and HEPG2 tumour cells expressing the AFP158–166 epitope, controlled tumour growth compared to controls [80].